Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbromal SCHEMBL620919 | 0.94 | CRBN (0.33) | CRBN | |
| Carbromal SCHEMBL1537493 | 0.93 | CRBN (0.32) | CRBN | |
| Carbromal SCHEMBL1499641 | 0.91 | SLC34A1 (0.32) | CRBN | |
| Carbromal SCHEMBL15057476 | 0.90 | CRBN (0.39) | CRBN | |
| Carbromal SCHEMBL261 | 0.90 | CRBN (0.39) | CRBN | |
| Carbromal SCHEMBL4351621 | 0.90 | CRBN (0.39) | CRBN | |
| Carbromal SCHEMBL11332793 | 0.89 | CRBN (0.30) | CRBN | |
| Carbromal SCHEMBL10866938 | 0.89 | SLC34A1 (0.31) | CRBN | |
| Carbromal SCHEMBL8594411 | 0.89 | MMP1 (0.32) | CRBN | |
| Carbromal SCHEMBL7529375 | 0.89 | CRBN (0.30) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | VAN POELJE PAUL D | 2009-08-06 | — | — | US | disclosed |
| US-7563774-B2 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| CN-101301294-A | Combinated inhibitors of FBP-ase and antidiabetic agents for diabetes treatment | METABEHJSIS TERAP JUTIKS INK (US) | 2008-11-12 | — | — | CN | disclosed |
| CN-100396283-C | Combination of FBP enzyme inhibitor and antidiabetic agent for treating diabetes | METABASIS THERAPEUTICS INC (US) | 2008-06-25 | — | — | CN | disclosed |
| US-7371739-B2 | Aryl fructose-1,6-bisphosphatase inhibitors | METABASIS THERAPEUTICS, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1265907-B9 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS INC (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1265907-B1 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS INC (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1607401-A1 | Novel aryl fructose-1,6-Bisphosphatase inhibitors | Metabasis Therapeutics, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| CN-1699383-A | Novel aryl fructose-1,6-bisphosphatase inhibitors | METABASIS THERAPEUTICS INC (US) | 2005-11-23 | — | — | CN | disclosed |
| US-20050176684-A1 | Novel aryl fructose-1,6-bisphosphatase inhibitors | BOOKSER BRETT C (US) | 2005-08-11 | — | — | US | disclosed |
| CN-1599612-A | Combination of FBP enzyme inhibitor and antidiabetic agent for treating diabetes | METABASIS THERAPEUTICS INC (US) | 2005-03-23 | — | — | CN | disclosed |
| CN-1516705-A | Novel arylfructose-1, 6-bisphosphatase inhibitors | ֢�����ƹ�˾ | 2004-07-28 | — | — | CN | disclosed |
| EP-1372660-A2 | A COMBINATION OF FBPASE INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1265907-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | Metabasis Therapeutics, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001066553-A2 | NOVEL ARYL FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS | METABASIS THERAPEUTICS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | FBP1, ALDOA, G6PC1 | CRBN 4365/4885 |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | FBP1, ALDOA, G6PC1 | CRBN 4365/4885 |
| US-20050176684-A1 | Novel aryl fructose-1,6-bisphosphatase inhibitors | FBP1, G6PC1, SLC5A1 | CRBN 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.